IGLV1-62

Across TCGA pan-cancer cohorts, IGLV1-62 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of IGLV1-62’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where IGLV1-62 RNA is repressed in tumor relative to normal tissue. In most cancer types IGLV1-62 is over-expressed in tumor, although a few such as COAD and STAD show the opposite, repressed pattern.

COAD, STAD, and BRCA are the cancer types where IGLV1-62 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGLV1-62 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	III,IV	−0.654	<.001	12	view →
STAD	Male	IV	−0.880	.003	8	view →
BRCA	Female	II,III,IV	−0.164	<.001	4	view →
READ	All	All	−0.768	.004	3	view →
LUAD	All	All	+0.316	<.001	2	view →
LIHC	Male	All	−0.074	.040	2	view →
KIRC	All	All	+0.061	.028	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

IGLV1-62–COAD

Open the COAD breakdown →